Intensity Therapeutics, Inc. (INTS)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Lewis H. Bender M.A., M.B.A., M.S. | Founder, President, CEO & Chairman of the Board | 597.01k | -- | 1959 |
Mr. Joseph Talamo CPA, M.B.A. | Chief Financial Officer | 416.93k | -- | 1969 |
Mr. John Wesolowski CPA, M.B.A. | Principal Accounting Officer & Controller | 260.9k | -- | 1960 |
Mr. James M. Ahlers | Executive Vice President of Corporate Finance | 75.09k | -- | 1964 |
Mr. Brian Schwartz M.D. | Executive Vice President of Clinical Development | -- | -- | -- |
Intensity Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 5
Description
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
January 7, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
December 17, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission